The goal of this study is to find out whether pramipexole tablets made at two different production sites are handled in the same way by the body.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Time frame: Up to Day 11
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Time frame: Up to Day 11
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
Time frame: Up to Day 11
Time from dosing to minimum measured concentration of the analyte in plasma at steady state within a uniform dosing interval τ (tmin,ss)
Time frame: Up to Day 11
Time from last dosing to maximum concentration of the analyte in plasma at steady state (tmax,ss)
Time frame: Up to Day 11
Average concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cavg)
Time frame: Up to Day 11
Measured concentration of the analyte in plasma at steady state at timepoint (= end of interval) τ (Cτ,ss)
Time frame: Up to Day 11
Peak-trough fluctuation (PTF)
Time frame: Up to Day 11
Peak-trough swing (PTS)
Time frame: Up to Day 11
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.